These findings for immunotherapeutics targeting GPC3 in different cancers show that GPC3 is a promising target to develop novel cancer therapies, and further research into the therapeutic potential in particular breast cancer subtypes will be of great value. This evidence concerns the gene GPC3 and breast carcinoma.